Novan Inc
F:6LUA

Watchlist Manager
Novan Inc Logo
Novan Inc
F:6LUA
Watchlist
Price: 0.001 EUR Market Closed
Market Cap: €1.3k

Novan Inc
Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novan Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Novan Inc
F:6LUA
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Long-Term Debt
$39.4B
CAGR 3-Years
14%
CAGR 5-Years
4%
CAGR 10-Years
12%
Bristol-Myers Squibb Co
NYSE:BMY
Long-Term Debt
$44.5B
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
21%
Pfizer Inc
NYSE:PFE
Long-Term Debt
$57.4B
CAGR 3-Years
21%
CAGR 5-Years
3%
CAGR 10-Years
7%
Merck & Co Inc
NYSE:MRK
Long-Term Debt
$40B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Long-Term Debt
$40.9B
CAGR 3-Years
42%
CAGR 5-Years
20%
CAGR 10-Years
18%
No Stocks Found

Novan Inc
Glance View

Market Cap
1.3k EUR
Industry
Pharmaceuticals

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

6LUA Intrinsic Value
Not Available

See Also

What is Novan Inc's Long-Term Debt?
Long-Term Debt
0 USD

Based on the financial report for Dec 31, 2022, Novan Inc's Long-Term Debt amounts to 0 USD.

Back to Top